Regeneron Covid Antibody Treatment Accepted for FDA Review

Regeneron Pharmaceuticals  (REGN) – Get Regeneron Pharmaceuticals, Inc. Report shares rose Thursday after the FDA accepted for review the company’s monoclonal antibody treatment for non-hospitalized Covid patients.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *